Tekla Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Tekla Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$3.49M	Buy	34,250 +16,400	+92%	+$1.55M	0.14%	94
2023 Q1	$1.62M	Buy	+17,850	New	+$1.05M	0.06%	128
2021 Q3	–	Sell	-38,219	Closed	-$5.41M	–	198
2021 Q2	$5.41M	Hold	38,219	–	–	0.18%	115
2021 Q1	$3.81M	Hold	38,219	–	–	0.13%	135
2020 Q4	$4.72M	Sell	38,219 -38,221	-50%	-$5.02M	0.17%	120
2020 Q3	$7.45M	Buy	76,440 +25,533	+50%	+$3.19M	0.28%	83
2020 Q2	$7.94M	Buy	50,907 +15,778	+45%	+$2.4M	0.3%	68
2020 Q1	$5.07M	Buy	35,129 +8,717	+33%	+$1.68M	0.23%	84
2019 Q4	$5.4M	Buy	+26,412	New	+$4.82M	0.2%	98

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tekla Capital Management's RETA Position: Q2 2023 in Review

Tekla Capital Management increased its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 92% in Q2 2023, buying an estimated $1.55M and bringing the position to 34,250 shares worth $3.49M. The position accounts for 0.14% of the portfolio, ranked #94.

Tekla Capital Management first reported a position in RETA in Q4 2019 and has held it in 9 quarters since. The position peaked at $7.94M in Q2 2020. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Tekla Capital Management held 34,250 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $3.49M as of Q2 2023.
Tekla Capital Management bought 16,400 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $1.55M.
Reata Pharmaceuticals, Inc. Class A Common Stock made up 0.14% of Tekla Capital Management's portfolio in Q2 2023, its #94 holding.
Tekla Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and has held it in 9 quarters since.
Tekla Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $7.94M in Q2 2020.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.